Oramed Pharmaceuticals annual operating margin
2016
2017
2018
2019
2020
2021
2022
2023
2025
Oramed Pharmaceuticals's operating margin was −754.40% for fiscal 2025.
View full Oramed Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −754.40% | +422.39 pp |
| 2023 | 2023-12-31 | −1,176.79% | +325.17 pp |
| 2022 | 2022-12-31 | −1,501.96% | −605.81 pp |
| 2021 | 2021-08-31 | −896.15% | −462.31 pp |
| 2020 | 2020-08-31 | −433.84% | +107.45 pp |
| 2019 | 2019-08-31 | −541.29% | +11.06 pp |
| 2018 | 2018-08-31 | −552.35% | −113.79 pp |
| 2017 | 2017-08-31 | −438.56% | +1123.06 pp |
| 2016 | 2016-08-31 | −1,561.62% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2025 | 2025-03-31 | −225.00% | +1205.25 pp |
| Q3 2023 | 2023-09-30 | −429.23% | +771.50 pp |
| Q2 2023 | 2023-06-30 | −562.46% | +1131.45 pp |
| Q1 2023 | 2023-03-31 | −781.98% | +907.51 pp |
| Q4 2022 | 2022-12-31 | −1,430.25% | +424.53 pp |
| Q3 2022 · Sep 30 | 2022-09-30 | −1,200.73% | −4.89 pp |
| Q3 2022 · Jun 30 | 2022-06-30 | −1,693.92% | −596.41 pp |
| Q2 2022 | 2022-03-31 | −1,689.49% | −1029.25 pp |
| Q1 2022 · Dec 31 | 2021-12-31 | −1,854.78% | −956.40 pp |
| Q1 2022 · Nov 30 | 2021-11-30 | −1,195.85% | −204.25 pp |
| Q3 2022 · Sep 30 | 2021-09-30 | −1,097.51% | −365.48 pp |
| Q3 2021 · Jun 30 | 2021-06-30 | −660.24% | +93.68 pp |
| Q3 2021 · May 31 | 2021-05-31 | −898.38% | −33.84 pp |
| Q2 2021 · Mar 31 | 2021-03-31 | −991.59% | −548.57 pp |
| Q2 2021 · Feb 28 | 2021-02-28 | −732.03% | −398.11 pp |
| Q1 2021 · Dec 31 | 2020-12-31 | −753.91% | −154.95 pp |
| Q1 2021 · Nov 30 | 2020-11-30 | −864.54% | −504.15 pp |
| Q4 2020 | 2020-08-31 | −443.02% | −98.68 pp |
| Q3 2020 | 2020-05-31 | −333.92% | +264.03 pp |
| Q2 2020 | 2020-02-29 | −598.96% | −63.23 pp |
| Q1 2020 | 2019-11-30 | −360.39% | +328.04 pp |
| Q4 2019 | 2019-08-31 | −344.35% | +166.19 pp |
| Q3 2019 | 2019-05-31 | −597.95% | +136.90 pp |
| Q2 2019 | 2019-02-28 | −535.74% | −20.67 pp |
| Q1 2019 | 2018-11-30 | −688.43% | −241.29 pp |
| Q4 2018 | 2018-08-31 | −510.53% | −48.88 pp |
| Q3 2018 | 2018-05-31 | −734.85% | −385.58 pp |
| Q2 2018 | 2018-02-28 | −515.07% | +35.67 pp |
| Q1 2018 | 2017-11-30 | −447.14% | −54.02 pp |
| Q4 2017 | 2017-08-31 | −461.65% | +1067.95 pp |
| Q3 2017 | 2017-05-31 | −349.27% | — |
| Q2 2017 | 2017-02-28 | −550.74% | — |
| Q1 2017 | 2016-11-30 | −393.11% | — |
| Q2 2016 | 2016-02-29 | −1,529.60% | — |
Over the last five reported fiscal years, Oramed Pharmaceuticals's operating margin decreased from −541.29% to −754.40%, a change of −213.11 percentage points. The latest reported quarter, Q1 2025, shows −225.00%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oramed Pharmaceuticals filings at SEC.gov ↗